期刊文献+

磷脂与非酒精性脂肪性肝病关系的研究

Study on the Relationship between Phospholipids and Nonalcoholic Fatty Liver Disease
暂未订购
导出
摘要 目的研究磷脂与非酒精性脂肪性肝病(NAFLD)的关系,了解NAFLD患者脂质代谢紊乱的特点。方法采用酶法测定血清磷脂(PL),并以甘油三酯(TG)、胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、极低密度脂蛋白胆固醇(VLDL-C)、空腹血糖(FPG)及肝酶等作为其他观察指标。结果NAFLD组血清磷脂值为(250.23±55.24)mg/dl,对照组为(229.23±39.03)mg/dl,相比较有显著性差异(t=3.12,P<0.01)。NAFLD组TC、TG、VLDL-C、FBS、ALT、AST、GCT明显高于对照组,两组间差异有统计学意义(P<0.01)。NAFLD组AKP高于对照组(P<0.05)。而NAFLD组HDL-C低于对照组,两组间差异有统计学意义(P<0.01)。结论NAFLD患者存在明显的脂质代谢紊乱,磷脂的代谢障碍造成血清磷脂升高。 Objective To investigate the relationship between phospholipids and nonalcoholic fatty liver disease (NAFLD) and to learn the characters of lipid metabolic disorder in NAFLD patients, Methods Serum phospholipase was measured by enzyme couple assays, and other observational indexes included serum total triglycofide (TG), total cholesterol (TC), high- density lipoprotein cholesterol (HDL-C), low-density ]ipoprotein (LDL-C), very low-density ]ipoprotein cholesterol (VLDL- C), fasting plasma glucose (FPG) and hepatitis enzyme, Results the serum phospholipase of NAFLD patients (250.23 :t: 55,24mg/dL) was significantly higher than the controls (229.23 :t: 39.03mg/dL), t = 3.12, P 〈 0,01, TC, TG, VLDL-C, FPG, ALT, AST, and GGT in NAFLD group were higher compared with those in control group (P 〈 0.01), AKP in NAFLD group was also higher than that in control group (P 〈 0.05) while HDL-C was lower in NAFLD patients rather than in controls (P〈0.01). Conclusions There exists obviously lipid metabolic disorder in NAFLD patients, which causes metabolism disturbances of phospholipids and may lead to increase of serum phospholipids,
出处 《浙江预防医学》 2007年第7期5-6,共2页 Zhejiang Journal of Preventive Medicine
关键词 非酒精性脂肪性肝病 磷脂 脂质代谢紊乱 Nonalcoholic fatty liver disease Phospholipids Lipid metabolic disorder
  • 相关文献

参考文献8

  • 1MantonND,Lipsett J,Moore DJ,et al.Nonalcoholic eseatohepatins in childen and adolescents[J].Med J Aust,2000,173:476-479.
  • 2范建高.提高对非酒精性脂肪性肝病危害的认识[J].国外医学(消化系疾病分册),2005,25(5):323-324. 被引量:8
  • 3Angulop L.Nonalcoholic fatty liver disease[J].Castroerr Trerol Hepatol,2002,17:918 - 920.
  • 4Assy N,Kaita k Mymin D,et al.Fatty infiltration of liver inhyperlipidemic patients[J].Dig Dis Sci,2000,45 (10):1929 -1934.
  • 5范建高 曾民德 等.上海市4009名机关职员脂肪肝流行病学调查[J].中华肝脏病杂志,1998,6(1):17-17.
  • 6Paradis V,Perlemuter G,Bonvoust F,et al.High glucose and hyperinsulinermia stimulate connective tissue growth fater expression a patial mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis[J].Hepatology,2001,34:738 - 744.
  • 7Sanyal AJ,Campbell-Sargent C,Mirshahi F,el; al.Nonalcoholic steatohepatitis:association of insulin resistan ce and mitochondfial abnormalities[J].Gastroenterology,2001,120 (5):1183-1194.
  • 8查政,郭志刚.升高高密度脂蛋白的临床意义及其药物的研究进展[J].国外医学(药学分册),2005,32(4):226-230. 被引量:7

二级参考文献17

  • 1O'Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function[J]. Circulation, 2001, 104 (16):1978- 1983.
  • 2Vaisman BL, Lambert G, Amar M. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice[J]. J Clin Invest, 2001, 108(2) :303 - 309.
  • 3Nakanishi N, Nakamura K, Suzuki K, et al. Relation of body weight change to changes in atherogenic traits: a study of middle-aged Japanese obese male office workers[J]. Ind Health, 2000, 38(2):233 - 238.
  • 4Bowen PH, Guyton JR. Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol [J]. Curr Atheroscler Rep, 2000, 2(1):58-63.
  • 5Bossé Y, Pascot A, Dumont M, et al. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil [ J ]. Genet Med,2002, 4(4):311-315.
  • 6Lipka LJ. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor[J]. Cardiovasc Drug Rev, 2003, 21(4) :293 - 312.
  • 7Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia[ J]. Ann Pharmacother, 2003, 37(6) :839 - 848.
  • 8Tellier P. Ezetimibe: from pharmacology to clinical trials[J]. Ann Endocrinol(Paris), 2003, 64(6):442-447.
  • 9Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol[J]. N Engl J Med , 2004, 350(15): 1505 - 1515.
  • 10de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705,in humans: a randomized phase Ⅱ doee-response study[J]. Circulation, 2002, 105(18):2159-2165.

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部